Arete Wealth Advisors LLC bought a new stake in shares of Bionano Genomics, Inc. (NASDAQ:BNGO – Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 37,140 shares of the company’s stock, valued at approximately $41,226,000,000.
Other hedge funds and other institutional investors have also modified their holdings of the company. Merit Financial Group LLC bought a new position in shares of Bionano Genomics during the 1st quarter valued at $28,000. HBK Sorce Advisory LLC bought a new position in shares of Bionano Genomics during the 4th quarter valued at $248,000. Brinker Capital Investments LLC bought a new position in shares of Bionano Genomics during the 1st quarter valued at $41,000. Lazard Asset Management LLC bought a new position in shares of Bionano Genomics during the 1st quarter valued at $77,000. Finally, Verition Fund Management LLC bought a new position in shares of Bionano Genomics during the 4th quarter valued at $44,000. Institutional investors own 26.61% of the company’s stock.
Bionano Genomics Stock Performance
Shares of BNGO opened at $0.58 on Tuesday. The company’s fifty day moving average price is $0.67 and its 200 day moving average price is $1.05. Bionano Genomics, Inc. has a one year low of $0.55 and a one year high of $4.35. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.74 and a quick ratio of 2.87. The company has a market capitalization of $178.86 million, a PE ratio of -1.24 and a beta of 2.14.
Insider Transactions at Bionano Genomics
In related news, Director Hannah Mamuszka acquired 65,789 shares of the company’s stock in a transaction dated Tuesday, June 13th. The shares were bought at an average price of $0.76 per share, for a total transaction of $49,999.64. Following the acquisition, the director now owns 65,789 shares in the company, valued at approximately $49,999.64. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Bionano Genomics news, CFO Christopher P. Stewart bought 50,000 shares of the firm’s stock in a transaction dated Friday, May 12th. The shares were acquired at an average cost of $0.67 per share, for a total transaction of $33,500.00. Following the transaction, the chief financial officer now owns 281,373 shares in the company, valued at $188,519.91. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Hannah Mamuszka bought 65,789 shares of the firm’s stock in a transaction dated Tuesday, June 13th. The shares were acquired at an average price of $0.76 per share, for a total transaction of $49,999.64. Following the completion of the transaction, the director now owns 65,789 shares in the company, valued at approximately $49,999.64. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 130,789 shares of company stock worth $93,100. 2.44% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
BNGO has been the topic of a number of recent research reports. LADENBURG THALM/SH SH cut their price target on shares of Bionano Genomics from $6.00 to $4.80 in a report on Wednesday, May 10th. BTIG Research dropped their target price on shares of Bionano Genomics from $3.00 to $2.00 in a report on Thursday, May 18th.
Bionano Genomics Profile
Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight.
Featured Articles
- Five stocks we like better than Bionano Genomics
- What is the Hang Seng index?
- 3 Housing Stocks to Avoid as Interest Rates Rise
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- AMC: Is a Big Squeeze in the Coming Attractions?
- What is the price-to-earnings growth (PEG) ratio?
- Rivian: A Roaring Rise Or Time To Cash Out?
Receive News & Ratings for Bionano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
